Siplizumab: A Deep Investigation into MEDI-507 and 288392-69-8 Siplizumab, previously recognized as MEDI-507 and bearing the compound designation 288392-69-8, represents a unique antibody designed to precisely target the CD25 molecule, a critical element of the IL-2 pathway. Its development focused on suppressing T-cell growth by disrupting CD25 s